Oncology FISH Analysis - Comprehensive MDS/AML FISH Panel

Clinical Use

Use

Oncology FISH Analysis – Comprehensive MDS/AML FISH Panel is a Fluorescence In Situ Hybridization (FISH) test that detects common chromosomal abnormalities associated with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). MDS is a group of disorders resulting from improper blood cell differentiation, leading to a higher risk of progression to AML. The test aids in the diagnosis and prognosis of MDS/AML, providing critical information for treatment strategies. Abnormalities detected include significant genetic mutations, such as monosomy 5 and translocations involving RUNX1T1/RUNX1, assisting in risk stratification and management of the disease.

Special Instructions

Clinicians should interpret the results considering the full clinical picture along with pathology data. Always consider prior cytogenetic findings and patient's treatment history before concluding. The assay is indicated if previous testing methods were inconclusive or when there is a strong clinical suspicion of MDS or AML depending on clinical severity and patient history.

Limitations

This FISH assay tests only the specified loci for abnormalities. It is incapable of identifying other genetic abnormalities that are not listed. Thus, results must be viewed in conjunction with clinical evaluation and should not be solely relied upon for a diagnosis of MDS or AML. Keeping the specimen properly stored and executed is critical for accurate results.

Test Details